MedPath

TICON-Day 3, Time Lapse Versus Conventional Method in Day 3 Embryo Culture and Assessment

Phase 4
Terminated
Conditions
Infertility
Interventions
Device: GERI+ incubator
Device: Conventional incubator
Registration Number
NCT03164551
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Brief Summary

The main purpose of the study was to evaluate the overall clinical value of GERI+ as an integrated embryo culture and assessment system, providing an undisturbed culture environment, continuous monitoring of embryo development and automated scoring using a predictive algorithm.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
408
Inclusion Criteria
  • Couples with less than or equal to (<= ) two failed fresh In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) embryo transfer cycles
  • Age greater than or equal to (>=) 18 and <= 40 years
  • Body mass index (BMI): 18-30 kilogram per meter square (kg/m2)
  • Normal uterine cavity under ultrasound
  • Participant and her husband/partner must have read and signed the Informed Consent form (ICF)
  • At least four normally fertilized oocytes (2Pronuclear stage (PN)) in the current cycle
Exclusion Criteria
  • Male with non-ejaculated sperm
  • Participants with abnormal, undiagnosed gynecological bleeding or with genitourinary malformations
  • Participants with any contraindication to Controlled Ovarian Stimulation (COS) for Assisted Reproductive Technologies (ART) or to gonadotropins
  • Planned "freeze all" cycle (oocytes or embryos)
  • Planned preimplantation genetic screening (PGS) or Pre-implantation genetic diagnosis (PGD) cycle
  • Concurrent participation in another clinical study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
GERI+ IncubatorGERI+ incubator-
Conventional incubatorConventional incubator-
Primary Outcome Measures
NameTimeMethod
Clinical Pregnancy Rate With Positive Fetal Heart Beat (FHB)Gestation Weeks 6 to 8

Clinical Pregnancy was defined as the pregnancy diagnosed by ultrasonographic or clinical documentation of at least one fetus with heart beat in gestational week 6 to 8. Clinical pregnancy rate with positive FHB was measured as the number of participants with FHB positive clinical pregnancy divided by number of participants with embryo transfer (ET) multiplied by 100. Here, data used for analysis was based on Merck Global Medical Affairs (GMA) interpretation.

Secondary Outcome Measures
NameTimeMethod
Good Quality Embryos RateDay 3 of embryo culture

Good Quality Embryos is defined embryos with 7 or more blastomeres, less than (\<) 25 % fragmentation, size and symmetry of blastomeres appropriate to the cell number, and no evidence of multinucleation, based on the morphology on Day 3 of embryo culture. Good quality embryos rate was defined as the number of good quality embryos divided by the number of embryos per participant multiplied by 100. Here, data used for analysis was based on Merck GMA interpretation.

Non-viable Embryos RateDays 1 to 3 of embryo culture

Non-viable Embryos is defined as the embryos in which development has been arrested for at least 24 hour or in which all the cells have degenerated or lysed. Non-viable embryos rate was defined as the number of non-viable embryos divided by the number of embryos per participant multiplied by 100. Here, data used for analysis was based on Merck GMA interpretation.

Ongoing Pregnancy RateGestational Weeks 10 to 12

Ongoing pregnancy is defined as the presence of viable fetuses identified by ultrasonography at gestational weeks 10-12. Ongoing pregnancy rate is defined as the number of participants with ongoing pregnancy divided by the number of participants with embryo transfer (ET) multiplied by 100. Here, data used for analysis was based on Merck GMA interpretation.

Utilizable Embryos RateDay 3 of embryo culture

Utilizable embryos rate is defined as the number of transferred and cryopreserved embryos divided by the number embryos stage zygotes per participant multiply by 100. Here, data used for analysis was based on Merck GMA interpretation.

Biochemical Pregnancy RateFrom Day 12 of Gestational up to Week 8

Biochemical Pregnancy defined as a pregnancy diagnosed only by the detection of Human Chorionic Gonadotropin (hCG) in serum or urine and that does not develop into a clinical pregnancy. Biochemical pregnancy rate was defined as the number of participants with biochemical pregnancy divided by the number of participants with embryo transfer (ET) multiplied by 100. Here, data used for analysis was based on Merck GMA interpretation.

Ectopic Pregnancy RateGestational Weeks 6 to 8

Ectopic pregnancy is defined as a pregnancy in which implantation takes place outside the uterine cavity. It is identified by ultrasonography at weeks 6-8. Ectopic Pregnancy Rate was defined as the number of participants with ectopic pregnancy divided by the number of participants with embryo transfer (ET) multiplied by 100. Here, data used for analysis was based on Merck GMA interpretation.

Multiple Pregnancy RateGestational Weeks 10 to 12

Multiple pregnancy is defined as a pregnancy with more than one fetus. It is identified by ultrasonography at gestational weeks 10-12. Multiple pregnancy rate was defined as the number of participants with multiple pregnancy divided by the number of participants with ongoing pregnancy multiplied by 100. Here, data used for analysis was based on Merck GMA interpretation.

Spontaneous Miscarriage RateGestational Weeks 10 to 12

Spontaneous miscarriage (SM) is the spontaneous loss of a clinical pregnancy before 20 completed weeks of gestational age (18 weeks after fertilization). In this study, the spontaneous miscarriage was tracked up to 10-12 weeks of gestational age. Spontaneous miscarriage rate was defined as the number of participants with spontaneous miscarriage divided by the number of participants with clinical pregnancy multiplied by 100. Here, data used for analysis was based on Merck GMA interpretation.

Implantation Rate (IR) With Positive Fetal Heart BeatGestational Weeks 6 to 8

A successful implantation is defined as the presence of one gestational sac with fetal heart beat (FHB) under ultrasonography at gestational weeks 6-8. Implantation rate (IR) was defined as the number of intrauterine gestational sacs with positive FHB under ultrasound scans at gestational weeks 6-8 divided by the total number of embryos transferred (ET) multiplied by 100. Here, data used for analysis was based on Merck GMA interpretation.

Trial Locations

Locations (17)

Demetra S.R.L

šŸ‡®šŸ‡¹

Firenze, Italy

Skive Fertility clinic

šŸ‡©šŸ‡°

Skive, Denmark

Fertility Clinic Skive Regional Hospital

šŸ‡©šŸ‡°

Skive, Denmark

Krankenhaus Bruneck

šŸ‡®šŸ‡¹

Bruneck (BZ), Italy

Oslo University Hospital

šŸ‡³šŸ‡“

Oslo, Norway

St. Olavs Hospital Hf, Universitetssykehuset i Trondheim

šŸ‡³šŸ‡“

Trodheim, Norway

Hospital de Cruces

šŸ‡ŖšŸ‡ø

Baracaldo, Spain

Nephrology Service Fundacion Puigvert

šŸ‡ŖšŸ‡ø

Barcelona, Spain

Hosp Univ de Canarias

šŸ‡ŖšŸ‡ø

Santa Cruz de Tenerife, Spain

Hospital Universitario Virgen de las Nieves

šŸ‡ŖšŸ‡ø

Granada, Spain

Centro Hospitalar e Universitario de Coimbra

šŸ‡µšŸ‡¹

Coimbra, Portugal

Cambrian Wellness Centre

šŸ‡ØšŸ‡¦

Calgary, Canada

Futura Diagnostica medica PMA SRL

šŸ‡®šŸ‡¹

Firenze, Italy

USL Toscana Nordovest

šŸ‡®šŸ‡¹

Viareggio, Italy

Sykehuset Telemark HF Fertilitetsavdeliningen Sor

šŸ‡³šŸ‡“

Skien, Norway

Regional Fertility Program

šŸ‡ØšŸ‡¦

Calgary, Canada

Hopital Antoine Beclere

šŸ‡«šŸ‡·

Clamart, France

Ā© Copyright 2025. All Rights Reserved by MedPath